Corcept Therapeutics CORT Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$31.76M-255% | $24.29M-21.0% | $19.67M-58.3% | $35.15M-1.0% | $20.55M-26.0% | ||
| $598K+29.4% | $289K+2.8% | $289K-9.1% | $109K+43.4% | $462K+285% | ||
| $23.04M+5.6% | $20.77M+23.6% | $22.88M+42.1% | $19.02M+25.1% | $21.83M+64.8% | ||
| -$13.11M+4.3% | -$15.18M-294% | —— | -$17.76M-27.2% | -$13.71M-91.4% | ||
| -$20.71M-364% | —— | $5.06M-13.9% | $2.75M— | $7.84M-61.5% | ||
| $3.27M+641% | $0— | $3.94M+465% | $4.63M+175% | -$605K+38.5% | ||
| -$7.64M-161% | $6M+293% | $10.92M+1,783% | —— | $12.57M+359% | ||
| -$9.38M-59.7% | —— | $17.16M-12.6% | $5.88M— | -$5.87M-164% | ||
| -$4.74M-135% | $3.22M— | $13.46M+304% | —— | $13.53M+474% | ||
| -$16.77M-452% | $38.45M-36.0% | $54.48M-25.7% | $44.3M+7.5% | $4.77M-79.9% | ||
| $201K+93.3% | $50K-58.7% | $0-100% | $57K-86.3% | $104K— | ||
| $4.54M+243% | —— | $14.65M+133% | $70.13M+217% | -$3.17M+64.8% | ||
| $0-100% | $0— | $42.46M+263% | $103.02M+2,862% | $27.43M+5,663% | ||
| $5.76M-63.6% | $36.54M+423% | $8.15M-30.0% | $12.43M+551% | $15.83M+801% | ||
| $760K+102% | -$31.22M-584% | -$46.41M-120% | -$102.93M-4,688% | -$39.8M-7,230% | ||
| -$287K-180% | —— | —— | $1.44M— | $358K— | ||
| -$11.76M+68.9% | -$4.64M+51.8% | —— | —— | -$37.85M-367% | ||
| —— | $3.24M-78.5% | $3.24M-78.5% | $3.24M-78.5% | $3.24M-78.5% | ||
| —— | $1.28M-53.3% | $1.28M-53.3% | $1.28M-53.3% | $1.28M-53.3% | ||
| -$836K+50.6% | —— | -$1.01M+64.9% | -$1.31M+56.6% | -$1.69M+40.8% | ||
| $137K+102% | —— | —— | —— | -$8.61M-346% | ||
| -$9.38M-59.7% | —— | $17.16M-12.6% | $5.88M— | -$5.87M-164% | ||
| -$4.74M-135% | $3.22M— | $13.46M+304% | —— | $13.53M+474% | ||
| $2.54M+47.9% | $2.46M+60.6% | $2.17M+68.3% | $3.28M+92.9% | $1.72M+82.4% | ||
| —— | $3.24M-78.5% | $3.24M-78.5% | $3.24M-78.5% | $3.24M-78.5% | ||
| $4.34M-17.5% | $6.76M-3.6% | $5.74M-28.7% | $6.8M+56.8% | $5.26M+193% | ||
| -$16.97M-464% | $38.4M-35.9% | $54.48M-24.0% | $44.24M+8.5% | $4.67M-80.4% | ||
| -$16.97M-464% | $38.4M-35.9% | $54.48M-24.0% | $44.24M+8.5% | $4.67M-80.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Corcept Therapeutics generate?
- Corcept Therapeutics (CORT) generated $120.5M in operating cash flow over the trailing twelve months.
- What is Corcept Therapeutics's free cash flow?
- After $308.0K of capital expenditures, Corcept Therapeutics's free cash flow was $120.1M over the trailing twelve months, down 32.1% year over year.
- Where does Corcept Therapeutics's cash flow data come from?
- Every line is extracted from Corcept Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
